Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status

Pharmacogenetics

Volumn 13, Issue 10, 2003, Pages 627-632

  Barclay, Murray L ^a   Sawyers, Steven M ^a   Begg, Evan J ^a   Zhang, Mei ^a   Roberts, Rebecca L ^b   Kennedy, Martin A ^b   Elliott, John M ^c  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b Depts of Pathology and Medicine   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CYP2D6; Genotype; Metabolic ratio; Metabolism; Perhexiline; Phenotype

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; HYDROXYPERHEXILINE; PERHEXILINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BLOTTING, SOUTHERN; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DNA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PERHEXILINE; PHENOTYPE; VARIATION (GENETICS);

EID: 0142188770     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200310000-00006     Document Type: Article

References (21)

1. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52:273-280.
2. Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. NZ Med J 1996; 109:315-319.
3. Morgan MY, Rehef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25:1057-1064.
4. Shah RR, Oates, NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982; 284:295-299.
5. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81:1260-1270.
6. Horowitz JD, Sia STB, MacDonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris - correlations with pharmacokinetics. Int J Cardiol 1986; 13:219-229.
7. Sallustio BC, Westley IS, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 2002; 54:107-114.
8. Grgurinovich N. Method for the analysis of perhexiline and its hydroxy metabolite in plasma using high-performance liquid chromatography with precolumn derivatization. J Chromatogr B Biomed Sci Appl 1997; 696:75-80.
9. Ciulla T, Slar R, Hauser S. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174:485-488.
10. Raimundo S, Fischer J, Eichelbaum M, Griese E-U, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10:577-581.
11. Roberts R, Joyce P, Kennedy MA. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction. Hum Mutat 2000; 16:77-85.
12. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
13. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12:465-472.
14. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5:215-223.
15. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63.
16. Lovlie R, Daly AK, Matre GE, Molven A, Steen VM. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6* 35 allele in ultrarapid metabolism? Pharmacogenetics 2001; 11:45-55.
17. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9:669-682.
18. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8:15-26.
19. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
20. Busse D, Eichelbaum E. Calcium channel blockers. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M. Metabolic drug interactions. Philadelphia: Lippincott, Williams and Wilkins; 2000, p. 895.
21. Allorge D, Harlow J, Boulet O, Hayhurst GP, Chowdry J, Roth E, et al. In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics 2001; 11:739-741.